# A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

> **NCT06310304** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 24 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Ruxolitinib IR
- **DRUG:** Ruxolitinib XR

## Key facts

- **NCT ID:** NCT06310304
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-26
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-05-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310304, "A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06310304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*